News of Note—Aeterna review, Allegro eye test and Ocugen orphan tag

Aeterna review, Allegro eye test and Ocugen orphan tag.

> Troubled Aeterna Zentaris, in the midst of a legal battle with its former CEO and major problems with its leading candidate, has announced a strategic review to “consider and evaluate various strategic and financing,” as well as “considering and recommending changes to the company’s management and governance.” Release

> Allegro Ophthalmics says the second stage of the phase 2b test of its leading eye drug Luminate hit its primary endpoint when used as a sequential therapy in patients with diabetic macular edema. Statement

> Ocugen says the FDA has been handed an orphan drug designation for its med OCU300 (brimonidine tartrate) in patients with ocular graft versus host disease. It works as a repurposed drug, which the biotech says can help up to 90% of patients “without significant side effects.” Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Suggested Articles

The Rady Children’s Institute for Genomic Medicine tapped Deloitte to help develop a network of flying drones to deliver genetic testing specimens.

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

The FDA approved a new, tiny pacemaker from Medtronic that does not require the wiring of separate electrodes between the implant and the heart.